Incretin Receptor Signaling Bias

Developing molecules with unique signaling properties

The chemical diversity of GLP-1R/GIPR Pefhtides generated by CE has enabled a deep understanding of incretin signaling and the role of signaling bias. Carmot believes that incretin signaling and, in particular, its effect on signaling bias may lead to the development of novel peptide and small molecule therapeutics with attractive efficacy and tolerability for people with obesity and diabetes.

Carmot has combined CE with its expertise in signaling bias to generate molecules with unique signaling properties. This approach has yielded potent peptide modulators such as CT-388, a once-weekly investigational dual GLP-1/GIP receptor modulator candidate being studied in overweight and obese people with and without type 2 diabetes.

Our Pipeline